Prognostic Signature Detects Homologous Recombination Deficient in Glioblastoma

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697739

Authors

Dongdong Luo

Aiping Luo

Su Hu

Hailin Zhao

Xuefeng Yao

Dan Li

Biao Peng

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma (GBM) is a frequent malignant tumor in neurosurgery characterized by a high degree of heterogeneity and genetic instability. DNA double-strand breaks generated by homologous recombination deficiency (HRD) are a well-known contributor to genomic instability, which can encourage tumor development. It is unknown, however, whether the molecular characteristics linked with HRD have a predictive role in GBM. The study aims to assess the extent of genomic instability in GBM using HRD score and investigate the prognostic significance of HRD-related molecular features in GBM.

Methods: The discovery cohort comprised 567 GBM patients from The Cancer Genome Atlas (TCGA) database. We established HRD scores using the single nucleotide polymorphism (SNP) array data and analyzed transcriptomic data from patients with different HRD scores to identify biomarkers associated with HRD. A prognostic model was built by using HRD-related differentially expressed genes (DEGs) and validated in a distinct cohort from the Chinese Glioma Genome Atlas (CGGA) database.

Results: Based on the SNP array data, the gene expression profile data, and the clinical characteristics of GBM patients, we found that patients with a high HRD score had a better prognosis than those with a low HRD score. The DNA damage repair (DDR) signaling pathways were notably enriched in the HRD-positive subgroup. The prognostic model was developed by including HRD-related DEGs that could evaluate the clinical prognosis of patients more efficiently than the HRD score. In addition, patients with a low-risk score had a considerably augmented signature of γδT cells. Finally, through univariate and multivariate Cox regression analyses, it was demonstrated that the prognostic model was superior to other prognostic markers.

Conclusions: In conclusion, our research has not only demonstrated that a high HRD score is a valid prognostic biomarker in GBM patients but also built a stable prognosis model [odds ratio (OR) 0.18, 95% confidence interval (CI): 0.11-0.23, P<0.001] that is more accurate than conventional prognostic markers such as O6-methylguanine-DNA methyltransferase (MGMT) methylation (OR 0.55, 95% CI: 0.33-0.91, P=0.02).

References

Hu W, Yang Y, Zhang T, Qin C, Li X . LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages. Front Med (Lausanne). 2020; 7:182. PMC: 7254797. DOI: 10.3389/fmed.2020.00182. View

Maniar A, Zhang X, Lin W, Gastman B, Pauza C, Strome S . Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010; 116(10):1726-33. PMC: 3324253. DOI: 10.1182/blood-2009-07-234211. View

Drean A, Lord C, Ashworth A . PARP inhibitor combination therapy. Crit Rev Oncol Hematol. 2016; 108:73-85. DOI: 10.1016/j.critrevonc.2016.10.010. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

Zhang Y, Dube C, Gibert Jr M, Cruickshanks N, Wang B, Coughlan M . The p53 Pathway in Glioblastoma. Cancers (Basel). 2018; 10(9). PMC: 6162501. DOI: 10.3390/cancers10090297. View

Turcan S, Makarov V, Taranda J, Wang Y, Fabius A, Wu W . Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2017; 50(1):62-72. PMC: 5769471. DOI: 10.1038/s41588-017-0001-z. View

Shi Z, Qu X, Guo C, Zhang L, Peng C, Xie Z . Identification of clinical trait-related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma. Aging (Albany NY). 2021; 13(18):22361-22374. PMC: 8507262. DOI: 10.18632/aging.203543. View

Marquard A, Eklund A, Joshi T, Krzystanek M, Favero F, Wang Z . Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015; 3:9. PMC: 4443545. DOI: 10.1186/s40364-015-0033-4. View

Gerber N, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K . Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol. 2014; 16(9):1186-95. PMC: 4136896. DOI: 10.1093/neuonc/nou043. View

10.

Nguyen L, Martens J, Van Hoeck A, Cuppen E . Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020; 11(1):5584. PMC: 7643118. DOI: 10.1038/s41467-020-19406-4. View

11.

Stover E, Fuh K, Konstantinopoulos P, Matulonis U, Liu J . Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020; 159(3):887-898. DOI: 10.1016/j.ygyno.2020.09.029. View

12.

Wu S, Li X, Gao F, de Groot J, Koul D, Yung W . PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021; 23(6):920-931. PMC: 8168825. DOI: 10.1093/neuonc/noab003. View

13.

Rao A, Quddusi A, Shamim M . The significance of MGMT methylation in Glioblastoma Multiforme prognosis. J Pak Med Assoc. 2018; 68(7):1137-1139. View

14.

Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F . Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018; 4:16. PMC: 6028448. DOI: 10.1038/s41523-018-0066-6. View

15.

Yang Z, Xie Q, Hu C, Jiang Q, Shen H, Schachner M . CHL1 Is Expressed and Functions as a Malignancy Promoter in Glioma Cells. Front Mol Neurosci. 2017; 10:324. PMC: 5650976. DOI: 10.3389/fnmol.2017.00324. View

16.

Wang L, Karpova A, Gritsenko M, Kyle J, Cao S, Li Y . Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021; 39(4):509-528.e20. PMC: 8044053. DOI: 10.1016/j.ccell.2021.01.006. View

17.

Lim S, Yuzhalin A, Gordon-Weeks A, Muschel R . Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016; 7(19):28697-710. PMC: 5053756. DOI: 10.18632/oncotarget.7376. View

18.

Wang Y, Xu H, Liu T, Huang M, Butter P, Li C . Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells. JCI Insight. 2018; 3(3). PMC: 5821187. DOI: 10.1172/jci.insight.98096. View

19.

Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N . Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 2020; 10(1):2757. PMC: 7026096. DOI: 10.1038/s41598-020-59671-3. View

20.

Cairo C, Surendran N, Harris K, Mazan-Mamczarz K, Sakoda Y, Diaz-Mendez F . Vγ2Vδ2 T cell Costimulation Increases NK cell Killing of Monocyte-derived Dendritic Cells. Immunology. 2014; . PMC: 4557679. DOI: 10.1111/imm.12386. View